<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Crucell N.v.</title>
	<atom:link href="http://www.stockbloghub.com/tag/crucell-nv/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Announces Plans to Aquire Remaining Interest in Crucell NV</title>
		<link>http://www.stockbloghub.com/2010/09/18/jnj-johnson-johnson-announces-plans-to-aquire-remaining-interest-in-crucell-nv/52102</link>
		<comments>http://www.stockbloghub.com/2010/09/18/jnj-johnson-johnson-announces-plans-to-aquire-remaining-interest-in-crucell-nv/52102#comments</comments>
		<pubDate>Sun, 19 Sep 2010 05:50:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Crucell N.v.]]></category>
		<category><![CDATA[CRXL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52102</guid>
		<description><![CDATA[Johnson &#38; Johnson (JNJ) recently announced its plans to buy out the rest of Dutch biopharmaceutical company Crucell NV (CRXL) for €1.75 billion or €24.75 per share cash. Johnson &#38; Johnson had previously acquired a 17.9% stake in Crucell in September 2009 for €301.8 million. The companies are currently in an advanced stage of discussion regarding the proposed acquisition. Once the acquisition is complete, Johnson &#38; Johnson plans to retain the existing facilities and senior management of Crucell. Following the acquisition, Crucell will lead Johnson &#38; Johnson’s vaccines division. This acquisition should not only help strengthen Johnson &#38; Johnson’s portfolio, it should also allow the company to build its presence in the vaccines market, given Crucell&#8217;s expertise in the manufacture, discovery and commercialization of vaccines. Vaccines are becoming one of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/18/jnj-johnson-johnson-announces-plans-to-aquire-remaining-interest-in-crucell-nv/52102/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BHP) Company News for September 17, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/09/17/bhp-company-news-for-september-17-2010-corporate-summary/52058</link>
		<comments>http://www.stockbloghub.com/2010/09/17/bhp-company-news-for-september-17-2010-corporate-summary/52058#comments</comments>
		<pubDate>Fri, 17 Sep 2010 17:30:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Industrial Metals & Minerals]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[Centurytel Inc.]]></category>
		<category><![CDATA[Crucell N.v.]]></category>
		<category><![CDATA[CRXL]]></category>
		<category><![CDATA[CTL]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[IGT]]></category>
		<category><![CDATA[International Game Technology]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Massey Energy Company]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[MEE]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[Q]]></category>
		<category><![CDATA[Qwest Communications International Inc]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52058</guid>
		<description><![CDATA[• Johnson &#38; Johnson (NYSE:JNJ) is reportedly planning to buy its remaining stake in Dutch biopharmaceutical firm Crucell (NASDAQ:CRXL), in a deal valued at $2.29 billion • Goldman Sachs (NYSE:GS) upgraded CenturyLink (NYSE:CTL) to &#8220;buy&#8221; from &#8220;neutral&#8221; • Goldman Sachs (NYSE:GS) upgraded Qwest (NYSE:Q) to &#8220;buy&#8221; from &#8220;neutral,&#8221; taking the price target from $5.75 to $7.00 • UBS (NYSE:UBS) downgraded Noble Energy (NYSE:NBL) to &#8220;neutral&#8221; from &#8220;buy,&#8221; with a price target of $76 • Macquarie cut Massey Energy (NYSE:MEE) shares to &#8220;neutral&#8221; from &#8220;outperform&#8221; • HSBC (NYSE:HBC) downgraded BHP Billiton (NYSE:BHP) from &#8220;overweight&#8221; to &#8220;neutral,&#8221; setting a price target of $29.50 • Jefferies (NYSE:JEF) started coverage of McDonalds (NYSE:MCD) with a &#8220;hold&#8221; rating and a price target of $75 • Janney Montgomery downgraded International Game Technologies (NYSE:IGT) to &#8220;neutral&#8221; from &#8220;buy&#8221; Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/17/bhp-company-news-for-september-17-2010-corporate-summary/52058/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Two Pharmas Are Better Than One &#8211; Here Are the Ones to Buy in This Merger-Mad Industry</title>
		<link>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681</link>
		<comments>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681#comments</comments>
		<pubDate>Fri, 16 Oct 2009 20:27:30 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Crucell N.v.]]></category>
		<category><![CDATA[CRXL]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17681</guid>
		<description><![CDATA[Tony Daltorio, Investment U Research Pharmaceutical companies have launched themselves into the fall season with a vengeance, gobbling up acquisitions like dots on a Pac-Man board. The most notable recent buyout was a deal that sees Abbott Laboratories (NYSE: ABT) expand both its product range and its presence in notable emerging nations with its purchase of Belgian-based Solvay Group’s pharmaceutical arm for a $6.5 billion fee. That price tag is just one indication of the money washing around this industry these days, which makes the current consolidation trend chock full of profitable opportunities. As Investment U’s own “takeover tracker” Louis Basenese does all the time, he positions investors for some pretty lucrative short-term profits by buying takeover targets, then riding those deals all the way into long-term profits by purchasing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/abt-two-pharmas-are-better-than-one-here-are-the-ones-to-buy-in-this-merger-mad-industry/17681/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRXL) Crucell N.V. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/10/crucell-nv-aggressive-growth-zacks-rank-buy/4160</link>
		<comments>http://www.stockbloghub.com/2009/03/10/crucell-nv-aggressive-growth-zacks-rank-buy/4160#comments</comments>
		<pubDate>Tue, 10 Mar 2009 17:49:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Crucell N.v.]]></category>
		<category><![CDATA[CRXL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4160</guid>
		<description><![CDATA[Crucell N.V (CRXL) has reported another earnings surprise that crushed Wall Street estimates. The company has also received approval from Chinese authorities and has doubled the production of one of its leading vaccinations. Company Description Crucell N.V. discovers, develops, and produces a variety of biopharmaceuticals for the treatment of human diseases. Unlike the technologies generally employed in the biopharmaceutical industry, the company&#8217;s technologies are fully-human and, as such, enable biopharmaceuticals to be developed and produced that do not have the limitations inherent in many biopharmaceuticals currently available. Turned the Corner Crucell announced its fourth-quarter and full-year results for 2008 that included net profit of 14.6 million Euros, up from a loss of 42.9 billion Euros. Earnings per share came out to 38 cents, blowing away Wall Street estimates of just ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/10/crucell-nv-aggressive-growth-zacks-rank-buy/4160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

